By Douglas Feil, NBCF Chief Program Officer Medical Disclaimer: The information provided in this article is for...
Nila Kartika Wati
Argenx NV, a prominent biopharmaceutical company, has made the strategic decision to terminate the late-stage Phase III...
In an era where the translation of complex genomic research into viable commercial solutions is the primary...
Bridging the Divide: New National Survey Calls for a Unified Standard in Canadian Breast Cancer Care
Bridging the Divide: New National Survey Calls for a Unified Standard in Canadian Breast Cancer Care
In a landscape where medical innovation is accelerating at an unprecedented pace, a sobering reality persists for...
For decades, the standard path for women undergoing breast reconstruction following a mastectomy has been binary: either...
October, Breast Cancer Awareness Month, paints our world in shades of pink. From ubiquitous product promotions to...
Oklahoma City, OK – In a significant stride toward understanding and potentially conquering one of the most...
By Douglas Feil, NBCF Chief Program Officer In recent years, glucagon-like peptide-1 (GLP-1) receptor agonists have surged...
The landscape of personal health technology has shifted significantly with the recent regulatory approval of the Happy...
The landscape of drug discovery is undergoing a profound paradigm shift. For decades, the pathology workflow was...
